An analysis of Leukapheresis as a prophylactic modality of therapy for ‘Tumor Lysis Syndrome’ compared to conventional management: A pilot open labelled Randomized control trial - Trial acronym: DBULKT

All India Institute of Medical Sciences Raipur0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•Leukapheresis for Hyperleukocytosis defined as Acute Myeloid leukemia on peripheral smear (PS) with WBC >100X109/l or Acute Lymphoblastic leukemia on PS with WBC >100X109/l or transformation of Chronic leukaemia with Blast count >20% (WBC >100X109/l) TLS Prophylaxis of AML/ALL with WBC <100,000/cumm & ? 25,000/ µl with prechemotherapy LDH ?2 X (times) upper limit of normal value categorised as intermediate risk TLS.

•The Exclusion criteria for the Treatment are as follows:
•i.Patients with clinical and Blood smear diagnosis other than Acute myeloid leukemia; Acute lymphoblastic leukemia or chronic leukemia with blast transformation classified a high or moderate risk TLS as mentioned in the inclusion criteria
•ii.Patient with Acute myeloid Leukemia (Promyelocytic FAB M3) on peripheral smear.
•iii.Unconscious or delirious patients who cannot provide a videographic consent.
•iv.Ongoing tumor lysis syndrome for prophylactic Leukapheresis.

发起方